The heart transplant team from Baylor University Medical Center at Dallas (Baylor Dallas), part of Baylor Scott & White Health, played a prominent role at the American Transplant Congress (ATC) meeting, held June 3 – 7, 2023 in San Diego, Calif. A joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation (AST), the forum exchanges new clinical information on tissue and solid organ transplantation and provides education on cutting-edge advances and research. The conference brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists and allied health professionals.

Baylor Scott & White Health played a leading role at the 43^rd Annual Meeting & Scientific Sessions of The International Society for Heart and Lung Transplantation (ISHLT), held April 19-22, 2023, in Denver, Colorado. More than 3,600 members from around the world gathered to exchange ideas and collaborate on the latest science.

Management of patients with heart failure with reduced ejection fraction consists of a combination of older, tried-and-true medications and recently developed, novel pharmacological therapies. Known as the “four pillars” of heart failure therapy, these medications are beta blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), mineralcorticoid receptor antagonists (MRAs) and sodium-glucose co-transporter 2 Inhibitors (SGLT2i). The latest clinical evidence shows patients with heart failure should be put on these drugs all at once.

Guideline-directed medical therapy (GDMT) for patients with heart failure consists of rapid initiation of beta blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), mineralcorticoid receptor antagonists (MRAs) and sodium-glucose co-transporter 2 Inhibitors (SGLT2i). However, a gap occurs when patients are put on these medications but still have symptomatic heart failure. A new set of support devices approved by the FDA in the last three years is helping to bridge this gap in GDMT.